Biotechnology and Bioprocess Engineering:BBE

  • 제9권1호
  • /
  • Pages.65-68
  • /
  • 2004
  • /
  • 1226-8372(pISSN)
  • /
  • 1976-3816(eISSN)
한국생물공학회 (The Korean Society for Biotechnology and Bioengineering)
권호 표지

Cold Ethanol Fractionation and Heat Inactivation of Hepatitis A Virus During Manufacture of Albumin from Human Plasma

  • Kim, In-Seop (Department of Biological Sciences, Hannam University) ;
  • Park, Yong-Woon (Central Research Center, Green Cross Plasma Derivatives Company) ;
  • Lee, Sung-Rae (Central Research Center, Green Cross Plasma Derivatives Company) ;
  • Sung, Hark-Mo (Central Research Center, Green Cross Plasma Derivatives Company)
  • 발행 : 2004.01.01
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

The purpose of the present study was to examine the efficacy and mechanism of fraction IV cold ethanol fractionation and pasteurization (60$^{\circ}C$ heat treatment for 10 h), involved in the manufacture of albumin from human plasma, in the removal and/or inactivation of the hepatitis A virus (HAV). Samples from the relevant stages of the production process were spiked with HAV and the amount of virus in each fraction then quantified using a 50% tissue culture infectious dose (TCID$\_$50/). HAV was effectively partitioned from albumin during the fraction IV cold ethanol fractionation with a log reduction factor of 3.43. Pasteurization was also found to be a robust and effective step in inactivating HAV, where the titers were reduced from an initial titer of 7.60 log TCID$\_$50/ to undetectable levels within 5 h of treatment. The log reduction factor achieved during pasteurization was $\geq$4.76. Therefore, the current results indicate that the production process for albumin has sufficient HAV reducing capacity to achieve a high margin of virus safety.

키워드

참고문헌

  1. Blood Rev. v.2 Infectious complications of blood transfusion Berkman,S.A. https://doi.org/10.1016/0268-960X(88)90026-4
  2. Curr. Stud. Hematol. Blood Transfus. v.56 Overview of viruses relevant to blood transfusion Schilt,U.
  3. Blood separation and plasma fractionation Viral contamination of human plasma and procedures for preventing virus transmission by plasma products Cuthbertson,B.;K.G.Reid;P.R.Foster;J.R.Harris(ed.)
  4. J. Am. Chem. Soc. v.68 Preparation and properties of serum and plasma proteins. Ⅳ. A system for the separation into fractions of the proteins and lipoprotein components of biological tissues and fluids Cohn,E.J.;L.E.Strong;W.L.Hughes Jr.;D.J.Mulford,J.N.;Ashworth;M.Melin;H.L.Taylor https://doi.org/10.1021/ja01207a034
  5. J. Microbiol. Biotechnol. v.10 Partitioning and inactivation of viruses by cold ethanol fractionation and pasteurization during manufacture of albumin from human plasma Kim,I.S.;H.G.Eo;C.E.Chang;S.Lee
  6. Pharmacotherapy v.16 Viral infectivity of albumin and plasma protein fraction Erstad,B.L.
  7. Rev. Med. Virol. v.6 Virus safety of plasma products Roberts,P. https://doi.org/10.1002/(SICI)1099-1654(199603)6:1<25::AID-RMV162>3.0.CO;2-2
  8. Transfusion v.39 The epidemiology of virus transmission by plasma dervaives: Clinical studies verifying the lack of transmission of hepatitis B and C viruses and HIV type 1 Tabor,E. https://doi.org/10.1046/j.1537-2995.1999.39111160.x
  9. Bundesanzeiger v.84 Notice on the registration of drugs: Requirements for validation studies to demonstrate the virus safety of drugs derived from human blood of plasma Federal Health Office and Paul Ehrlich Institute Federal Office for Sera and Vaccines
  10. Federal Resister v.63 no.185 Guidance on viral safety evaluation of biotechnology products derived from cell lines of human of animal origin: Availability International Conference on Harmonisation
  11. Biotechnol. Bioprocess Eng. v.6 Removal and inactivation of human immunodeficiency virus (HIV-1) by cold ethanol fractionation and pasteurization duting the manufacture of albumin and immunoglobulins from hyman plasma Kim,I.S.;H.G.Eo;C.W.Park;C.E.Chang;S.Lee https://doi.org/10.1007/BF02942246
  12. Dev. Biol. Stand. v.81 Partitioning and inactivation of viruses during isolation of albumin and immunoglobulins by cold ethanol fractionation Morgenthaler,J.J.;A.Omar
  13. Vox Sang. v.54 Inactivation and partition of human immunodeficiency virus during Kistler and Nitschmann fractionation of human blood plasma Henin,Y.;V.Marechal;F.Barre-Sinoussi;J.C.Chermann;J.J.Morgenthaler https://doi.org/10.1111/j.1423-0410.1988.tb01621.x
  14. Transfusion v.26 Inactivation and partition of human T-cell lymphotrophic virus, type Ⅲ, during ethanol fractionation of plasma Wells,M.A.;A.E.Wittek;J.S.Epstein;C.Marcus-Sekura;S.Daniel;D.L.Tankersley;M.S.Preston;G.V.Quinan Jr. https://doi.org/10.1046/j.1537-2995.1986.26286152919.x
  15. Transfusion v.32 pratitioning of hepatitis C virus during Cohn-Oncley fractionation of plasma Yei,S.;M.W.yu;D.L.Tankersley https://doi.org/10.1046/j.1537-2995.1992.32993110753.x
  16. Andrewes' Viruses of Vertebrates Andrewes,C.
  17. Int. J. Epidermol. v.24 An outbreak of hepatitis A among Irish haemophiliacs Johnson,Z.;L.Thormton;A.Tobin;E.Lawlor;J.Power;I.Hillary;I.Temperley https://doi.org/10.1093/ije/24.4.821
  18. Lancet v.340 Clotting factors and hepatitis A Robinson,S.M.;H.Schwinn;A.Smith https://doi.org/10.1016/0140-6736(92)92652-V
  19. Lancet v.340 Clotting factors and hepatitis A Temperley,I.J.;K.P.Cotter;T.J.Walsh;J.Power;I.B.Hillary https://doi.org/10.1016/0140-6736(92)92653-W
  20. Biotechnol. Bioprocess Eng. v.7 Removal and inactivation of hepatitis A virus during manufature of urokinase from human urine Kim,I.S.;Y.W.Choi;S.R.Lee;Y.Kang;.K.M.Lee;D.H.Park;H.S.Woo;S.Lee https://doi.org/10.1007/BF02933518
  21. Curr. Srud. Hematol. Blood Transfus. v.56 Strategies to produce virus-safe blood derivatives Heimburger,N.;H.E.Karges
  22. Dev. Biol. Stand. v.81 Inactivation of HIV, HBV, HCV related viruses and other viruses in human plasma derivaties by pasteurization Nowk,T.;M.Niedrig;D.Bernhardt;J.Hilfenhaus